OnKure, Inc. announced the appointment of Rogan Nunn as General Counsel and Secretary.
BOULDER, Colo., June 19, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Rogan Nunn as General Counsel and Secretary. Mr. Nunn will be a member of OnKure’s Executive Team, reporting to Nicholas Saccomano, President and Chief Executive Officer, and will oversee all aspects of the Company’s legal and compliance functions.
“We are delighted to welcome Rogan to OnKure as our new General Counsel and Secretary,” said Dr. Saccomano. “Rogan’s extensive legal expertise and strategic insight will be invaluable as we continue to advance our programs.”
“I’m thrilled to be joining OnKure at such a pivotal and exciting time in its evolution,” said Mr. Nunn. “We have an extraordinarily talented and dedicated team here. Together, I believe we have a real opportunity to advance the state of treatment and make a meaningful difference in the lives of patients.”
Prior to joining OnKure, Mr. Nunn served as General Counsel, America at ADC Therapeutics, where he oversaw global legal operations and executed transactions across the U.S., Europe and Asia. Before ADC, Mr. Nunn served as EVP, General Counsel and Secretary of Array Biopharma until Array’s sale to Pfizer. Prior to moving in-house at Array Biopharma, Mr. Nunn was a corporate and M&A specialist at Skadden, Arps, Slate, Meagher & Flom, where he counseled boards and executive teams of both public and private companies in a diverse array of corporate matters, with a particular focus on life sciences and biotechnology.
Mr. Nunn holds a BS in Finance and International Business from Georgetown University and a Juris Doctor from the University of Virginia School of Law.
About OnKure
OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design portfolio, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.
Contacts: Investors: IR@onkure.com
